Exelixis, Inc. (NASDAQ:EXEL) Shares Bought by Federated Hermes Inc.

Federated Hermes Inc. grew its stake in Exelixis, Inc. (NASDAQ:EXEL) by 1.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 227,909 shares of the biotechnology company’s stock after acquiring an additional 2,333 shares during the quarter. Federated Hermes Inc. owned about 0.08% of Exelixis worth $5,121,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Fisher Asset Management LLC lifted its holdings in Exelixis by 232.6% in the 4th quarter. Fisher Asset Management LLC now owns 1,041 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 728 shares in the last quarter. Rise Advisors LLC purchased a new position in shares of Exelixis during the first quarter valued at approximately $28,000. Park Place Capital Corp purchased a new position in shares of Exelixis during the second quarter valued at approximately $45,000. GAMMA Investing LLC boosted its position in Exelixis by 107.9% during the second quarter. GAMMA Investing LLC now owns 2,006 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 1,041 shares during the last quarter. Finally, EntryPoint Capital LLC grew its stake in Exelixis by 537.2% in the 1st quarter. EntryPoint Capital LLC now owns 2,071 shares of the biotechnology company’s stock worth $49,000 after acquiring an additional 1,746 shares during the period. Institutional investors and hedge funds own 85.27% of the company’s stock.

Insider Activity at Exelixis

In other Exelixis news, EVP Dana Aftab sold 95,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $25.00, for a total value of $2,375,000.00. Following the completion of the transaction, the executive vice president now owns 520,990 shares in the company, valued at approximately $13,024,750. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, CFO Christopher J. Senner sold 125,000 shares of Exelixis stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $27.19, for a total transaction of $3,398,750.00. Following the sale, the chief financial officer now directly owns 721,680 shares of the company’s stock, valued at $19,622,479.20. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Dana Aftab sold 95,000 shares of the stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $25.00, for a total value of $2,375,000.00. Following the completion of the transaction, the executive vice president now directly owns 520,990 shares of the company’s stock, valued at approximately $13,024,750. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 302,858 shares of company stock worth $7,980,629. 2.85% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. HC Wainwright restated a “buy” rating and set a $29.00 price objective on shares of Exelixis in a report on Wednesday. Oppenheimer restated an “outperform” rating and issued a $29.00 price target on shares of Exelixis in a report on Tuesday, July 30th. StockNews.com raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 13th. Royal Bank of Canada restated an “outperform” rating and issued a $27.00 target price on shares of Exelixis in a report on Wednesday, August 7th. Finally, JMP Securities upped their price target on shares of Exelixis from $27.00 to $29.00 and gave the stock a “market outperform” rating in a research report on Wednesday, August 7th. Four investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $27.50.

Exelixis Trading Down 2.8 %

Shares of EXEL stock opened at $26.82 on Thursday. The company has a market cap of $8.13 billion, a PE ratio of 41.91, a P/E/G ratio of 0.58 and a beta of 0.54. The company’s fifty day simple moving average is $24.94 and its 200-day simple moving average is $23.26. Exelixis, Inc. has a 52 week low of $18.64 and a 52 week high of $27.83.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.31 by $0.44. The company had revenue of $637.18 million for the quarter, compared to analyst estimates of $468.21 million. Exelixis had a return on equity of 15.54% and a net margin of 17.38%. Equities research analysts expect that Exelixis, Inc. will post 1.54 EPS for the current fiscal year.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.